Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanwei Qingzhi is a Traditional Chinese Medicine (TCM) hospital preparation developed by Ningjin County Hospital in Xingtai City, Hebei Province, China. It is primarily indicated for the treatment of hyperlipidemia. The formulation is a mixture (Heji) composed of three key herbal ingredients, typically including *Crataegus pinnatifida* (Hawthorn), *Alisma plantago-aquatica* (Water Plantain), and *Polygonum multiflorum* (Fleeceflower root). These components work synergistically to lower serum cholesterol and triglycerides by inhibiting HMG-CoA reductase activity and promoting the excretion of lipids. As a hospital-made preparation (院内制剂), it is used clinically within the institution to manage patients with lipid metabolism disorders and to prevent related cardiovascular complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanwei qingzhi.